Mayzent And Mavenclad For Treatment Of Ms
Mayzent and Mavenclad are both approved to treat relapsing-remitting multiple sclerosis (RRMS), as well as active secondary progressive multiple sclerosis (SPMS). Active SPMS is a type of MS in which a person still experiences relapses, while also experiencing a steady progression of MS-related disability. Mayzent (but not Mavenclad) is also approved to treat clinically isolated syndrome (CIS). Overview of Mayzent Mayzent is a sphingosine 1-phosphate receptor modulator, similar to Gilyena (fingolimod), and is believed to work by sequestering certain white blood cells (your infection-fighting cells) within a person’s lymph nodes....